{"id":"NCT02541383","sponsor":"Intergroupe Francophone du Myelome","briefTitle":"A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma","officialTitle":"Study of Daratumumab in Combination With Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD) in the First Line Treatment of Transplant Eligible Subjects With Newly Diagnosed Multiple Myeloma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-09","primaryCompletion":"2020-08-27","completion":"2023-09-01","firstPosted":"2015-09-04","resultsPosted":"2025-04-13","lastUpdate":"2025-04-13"},"enrollment":1085,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Myeloma"],"interventions":[{"type":"DRUG","name":"Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD)","otherNames":["Arm A Part 1"]},{"type":"DRUG","name":"Bortezomib, Thalidomide, Dexamethasone (VTD) + daratumumab","otherNames":["Arm B Part 1"]},{"type":"DRUG","name":"Daratumumab","otherNames":["Arm B Part 2"]}],"arms":[{"label":"Arm A Part 1","type":"OTHER"},{"label":"Arm B Part 1","type":"EXPERIMENTAL"},{"label":"Arm A Part 2","type":"NO_INTERVENTION"},{"label":"Arm B Part 2","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate if the addition of daratumumab to Bortezomib, Thalidomide and Dexamethasone will increase the stringent complete response rate after consolidation therapy and increase the progression free survival after daratumumab maintenance therapy in transplant eligible participants with previously untreated Multiple Myeloma.","primaryOutcome":{"measure":"Post-Consolidation Stringent Complete Response (sCR) Rate","timeFrame":"At day 100 post Autologous Stem Cell Transplant (ASCT), up to 114 days post ASCT","effectByArm":[{"arm":"Arm A Part 1","deltaMin":110,"sd":null},{"arm":"Arm B Part 1","deltaMin":157,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0010"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":6},"locations":{"siteCount":107,"countries":["Belgium","France","Netherlands"]},"refs":{"pmids":["31171419","34529931","38889735","40127397","36263839","35086897","33657786","33242444"],"seeAlso":["https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daratumumab-transplant-eligible-multiple-myeloma"]},"adverseEventsSummary":{"seriousAny":{"events":261,"n":538},"commonTop":["Peripheral Sensory Neuropathy","Constipation","Bronchitis","Asthenia","Oedema Peripheral"]}}